MOUNTAIN VIEW, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Aerogen, Inc. today announced the worldwide availability of the first two GE Healthcare critical care products that contain an integrated version of Aerogen's Aeroneb(R) Professional Nebulizer System (Aeroneb Pro). GE Healthcare's Engstrom Carestation and Aptaer(TM) Heliox Delivery System are both designed with integral electronics that power the Aeroneb Pro. Under an agreement signed in May 2003, Aerogen is supplying GE Healthcare with access to a customized version of the Aeroneb Pro controller, on a non-exclusive basis, for integration into their critical care products. The Aeroneb Pro utilizes Aerogen's proprietary OnQ(TM) Aerosol Generator and is designed specifically to improve the efficiency of aerosolized drug therapy to mechanically ventilated patients.
The Engstrom Carestation is the first critical care respiratory product to offer clinicians the ability to integrate ventilation with monitoring modules capable of measuring certain patient parameters. The Aptaer(TM) Heliox Delivery System provides a non-invasive way to manage patients with severely compromised airways.
"The introduction of these two products containing Aerogen's technology helps us fulfill our commitment to providing cutting-edge solutions to enhance patient care," said Paul Baumgart, General Manager, GE Healthcare Respiratory Care Group.
In the United States alone, respiratory conditions account for approximately 48 million, or one-third, of all inpatient hospital days. Mechanical breathing support and aerosolized medications are two of the most common therapies administered to patients with respiratory conditions.
"The integration of the Aeroneb Pro controller is the next step in facilitating use of this technology for optimal aerosol delivery to ventilated patients," said Dr. Jane Shaw, Aerogen Chairman and CEO. "The incorporation of our Aeroneb Pro technology into GE Healthcare's critical care equipment will increase our product's market penetration and expand caregiver access to this important new technology," continued Shaw.
About GE Healthcare
GE Healthcare provides transformational medical technologies that will shape a new age of patient care. GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceuticals is dedicated to detecting disease earlier and tailoring treatment for individual patients. GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer's and cardiovascular diseases.
GE Healthcare is a $14 billion unit of General Electric Company that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit its website at http://www.gehealthcare.com/.
About Aerogen, Inc.
Aerogen, a specialty pharmaceutical company, develops products based on its OnQ(R) Aerosol Generator technology to improve the treatment of respiratory disorders in the acute care setting. Aerogen currently markets the Aeroneb Professional Nebulizer System for use in hospitals. Aerogen has presented the results of its first Phase 2 clinical study evaluating delivery of aerosolized amikacin for the treatment of ventilator-associated pneumonia; an additional Phase 2 study is currently underway. Following amikacin, additional drug products targeting improved respiratory therapy in the acute care setting are in the feasibility and pre-clinical stages of development. In the U.S., Aerogen has commercialized the Aeroneb(R) Go Nebulizer for home use through its commercial partner, Evo Medical Solutions, Inc. Aerogen also has development collaborations with pharmaceutical and biotechnology companies for use of its technology in the delivery of novel compounds that treat respiratory and other disorders. Aerogen is headquartered in Mountain View, California, with a campus in Galway, Ireland. For more information, visit http://www.aerogen.com/.
To the extent any statements made in this release relate to information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside of Aerogen's control and other uncertainties, and are subject to various risk factors that could cause Aerogen's actual results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the need for additional funding, the inherent risks of product development, clinical outcomes, regulatory risks and risks related to proprietary rights, market acceptance and competition, and are described in Aerogen's reports and other filings with the U.S. Securities and Exchange Commission, including Aerogen's Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission ("SEC") on April 14, 2004 and Aerogen's Quarterly Report filed on Form 10-Q for the quarter ended September 30, 2004 filed with the SEC on November 15, 2004. Aerogen does not undertake any obligation to update forward-looking statements.